{"id":"paroxetine-lamotrigine","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Insomnia or somnolence"},{"rate":null,"effect":"Rash (lamotrigine-related)"},{"rate":null,"effect":"Sexual dysfunction"},{"rate":null,"effect":"Weight changes"}]},"_chembl":{"chemblId":"CHEMBL6067650","moleculeType":"Small molecule","molecularWeight":"749.68"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Paroxetine inhibits serotonin reuptake at the presynaptic terminal, increasing synaptic serotonin availability. Lamotrigine blocks voltage-gated sodium channels and inhibits glutamate release, providing mood-stabilizing and neuroprotective effects. The combination is used to treat mood and anxiety disorders where monotherapy may be insufficient.","oneSentence":"This combination pairs a selective serotonin reuptake inhibitor (paroxetine) with an anticonvulsant mood stabilizer (lamotrigine) to enhance serotonergic neurotransmission while modulating glutamate and sodium channels.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:59:49.592Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"},{"name":"Bipolar disorder (depression and maintenance)"},{"name":"Anxiety disorders"}]},"trialDetails":[{"nctId":"NCT02893371","phase":"","title":"Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies","status":"TERMINATED","sponsor":"University of New Mexico","startDate":"2016-09","conditions":"Bipolar Disorder","enrollment":1037352},{"nctId":"NCT02374567","phase":"PHASE3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2015-01","conditions":"Dementia, Depression, Schizophrenia","enrollment":407},{"nctId":"NCT02300051","phase":"NA","title":"Intervention Study for Individuals With Compulsive Sexual Behavior","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2011-02","conditions":"Compulsive Sexual Behavior","enrollment":135},{"nctId":"NCT00926835","phase":"PHASE4","title":"Effect of Antidepressants on the Treatment for Korean Major Depressive Disorder Patients","status":"TERMINATED","sponsor":"Ministry of Health & Welfare, Korea","startDate":"2009-05","conditions":"Major Depressive Disorder","enrollment":692},{"nctId":"NCT00901407","phase":"NA","title":"Lamotrigine Augmentation in Resistant Depression","status":"COMPLETED","sponsor":"Louisiana State University Health Sciences Center in New Orleans","startDate":"2003-12","conditions":"Unipolar Depression","enrollment":138},{"nctId":"NCT00012558","phase":"NA","title":"Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"1998-09","conditions":"Bipolar Disorder","enrollment":5000},{"nctId":"NCT00177567","phase":"PHASE4","title":"Treatment of Geriatric Bipolar Mood Disorders: A Pilot Study","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2001-07","conditions":"Bipolar Disorder","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["seroxat, lamictal"],"phase":"marketed","status":"active","brandName":"Paroxetine+Lamotrigine","genericName":"Paroxetine+Lamotrigine","companyName":"Ministry of Health & Welfare, Korea","companyId":"ministry-of-health-welfare-korea","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination pairs a selective serotonin reuptake inhibitor (paroxetine) with an anticonvulsant mood stabilizer (lamotrigine) to enhance serotonergic neurotransmission while modulating glutamate and sodium channels. Used for Major depressive disorder, Bipolar disorder (depression and maintenance), Anxiety disorders.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}